摘要
目的:分析视网膜静脉阻塞(retinal vein occlusion,RVO)的相关因素及临床治疗效果。方法:对122例124眼RVO患者的临床资料进行回顾性分析。其中缺血型患者中分支静脉阻塞12眼(9.7%)、中央静脉阻塞6眼(4.8%),非缺血型分支静脉阻塞59眼(47.6%),中央静脉阻塞47眼(37.9%)。平均年龄60.6±11.8岁。高血压病史48例(39.3%),糖尿病10例(8.2%);伴有一种以上相关疾病20例(16.4%);无相关病史的有37例(30.3%)。仅采用药物保守治疗68例,联合激光治疗49例,行玻璃体切割术1例。结果:愈后显效72眼(58.1%);有效22眼(17.7%);无效的15眼(12.1%);愈后退步15眼(12.1%)。结论:CRVO是全身与局部致病因素共同作用的结果。临床治疗需辩证对待,对眼底出血的时间、受累部位及范围结合眼底血管造影进行全面评估,进行个性化治疗,从而全面提高患者疗效。
AIM: To analyze the related factors and clinical therapeutic effect of retinal vein occlusion (RVO). METHODS: The clinical data of 122 patients(124 eyes) with RVO were retrospectively analyzed, which including 12 eyes (9. 7%) of ischemia type branch retinal vein occlusion in patients with ischemic, 6 eyes (4. 8%) of ischemia type central retinal vein occlusion, 59 eyes (47.6%) of non- ischemia type central retinal vein occlusion, and 47 eyes (37.9%) of non- ischemia type central retinal vein occlusion. Among all the patients, the average age were 60.6 + 11.8 years old, there were 48 patients (39.3%) with hypertension, 10 patients (8.2%) with diabetes, 20 patients (16.4%) with more than one related diseases, and 37 patients (30. 3%) with none relevant history. Among them, 68 patients were treated only by drug conservative treatment, 49 patients were treated with the help of laser, and only 1 patient was treated by the vitrectomy surgery. RESULTS: Seventy- two eyes (58. 1%) had obvious effects; 22 eyes (17.7%) were significantly effective; 15 eyes (12.1%) were invalid; and 15 eyes (12.1%) became even worse. CONCLUSION. CRVO is formed by both the local and systemic pathogenic factors. Clinical therapy should be treated dialectically. And the complete diagnostic evaluation combined with fundus angiography should be conducted according to the fundus hemorrhage time, theinvolvement extent and location so that personalized treatment can be used to improve the patient's treatment effect.
出处
《国际眼科杂志》
CAS
2014年第2期354-357,共4页
International Eye Science
关键词
视网膜静脉阻塞
相关疾病
药物治疗
视网膜光凝术
retinal vein occlusion
related diseases
drug treatment
retinal photocoagulation